294 related articles for article (PubMed ID: 8511044)
21. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS).
Atilla E; Atilla PA; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Akay BN; Sanli H; Gurman G; Ozcan M
Int J Hematol; 2017 Sep; 106(3):426-430. PubMed ID: 28466385
[TBL] [Abstract][Full Text] [Related]
23. Clinical Trials Referral Resource: Mycosis Fungoides/Sézary Syndrome.
Cheson BD; Foss FM; Phillips PH
Oncology (Williston Park); 1995 Jul; 9(7):645-6. PubMed ID: 8924374
[No Abstract] [Full Text] [Related]
24. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
25. Treatment of mycosis fungoides/Sezary syndrome: the University of California, San Francisco (UCSF) approach.
Zackheim HS
Int J Dermatol; 2003 Jan; 42(1):53-6. PubMed ID: 12581145
[No Abstract] [Full Text] [Related]
26. A new nail in the CTCL coffin.
Lessin SR
J Invest Dermatol; 2006 Nov; 126(11):2368-9. PubMed ID: 17041618
[TBL] [Abstract][Full Text] [Related]
27. Sézary syndrome.
Davis MD; Alonsollamazares J; McEvoy MT
Eur J Dermatol; 2007; 17(1):96. PubMed ID: 17324842
[No Abstract] [Full Text] [Related]
28. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.
Trautinger F; Knobler R; Willemze R; Peris K; Stadler R; Laroche L; D'Incan M; Ranki A; Pimpinelli N; Ortiz-Romero P; Dummer R; Estrach T; Whittaker S
Eur J Cancer; 2006 May; 42(8):1014-30. PubMed ID: 16574401
[TBL] [Abstract][Full Text] [Related]
29. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
30. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
[TBL] [Abstract][Full Text] [Related]
31. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome.
Furue M; Kadono T
J Dermatol; 2015 Oct; 42(10):941-4. PubMed ID: 26432429
[TBL] [Abstract][Full Text] [Related]
32. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
33. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome.
Thangavelu M; Finn WG; Yelavarthi KK; Roenigk HH; Samuelson E; Peterson L; Kuzel TM; Rosen ST
Blood; 1997 May; 89(9):3371-7. PubMed ID: 9129044
[TBL] [Abstract][Full Text] [Related]
34. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
35. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
Photiou L; van der Weyden C; McCormack C; Miles Prince H
Curr Oncol Rep; 2018 Mar; 20(4):32. PubMed ID: 29572582
[TBL] [Abstract][Full Text] [Related]
36. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
Olsen EA; Rook AH; Zic J; Kim Y; Porcu P; Querfeld C; Wood G; Demierre MF; Pittelkow M; Wilson LD; Pinter-Brown L; Advani R; Parker S; Kim EJ; Junkins-Hopkins JM; Foss F; Cacchio P; Duvic M
J Am Acad Dermatol; 2011 Feb; 64(2):352-404. PubMed ID: 21145619
[TBL] [Abstract][Full Text] [Related]
37. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p.
Scarisbrick JJ; Woolford AJ; Russell-Jones R; Whittaker SJ
J Invest Dermatol; 2001 Sep; 117(3):663-70. PubMed ID: 11564174
[TBL] [Abstract][Full Text] [Related]
38. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
Wong HK
Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
[TBL] [Abstract][Full Text] [Related]
39. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Wong HK; Mishra A; Hake T; Porcu P
Br J Haematol; 2011 Oct; 155(2):150-66. PubMed ID: 21883142
[TBL] [Abstract][Full Text] [Related]
40. How we treat mycosis fungoides and Sézary syndrome.
Khan N; Noor SJ; Horwitz S
Clin Adv Hematol Oncol; 2021 Sep; 19(9):573-581. PubMed ID: 34495021
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]